Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171405
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2005-08-24
Brief Title:
A Clinical Study to Evaluate the Long-term Safety 12 Months of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 4 Month Extension to a 12 Month Randomized Open-label Multicenter Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide 125 mg or 25 mg in Patients With Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to collect the long-term 12 months safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None